This Week in NEJM

Premium

In NEJM this week, researchers in the Netherlands, Switzerland, and Belgium present their findings from a trial of intermediate doses of cytarabine in the treatment of acute myeloid leukemia. High doses of the drug — 2,000 to 3,000 milligrams per square meter of body-surface area — is toxic, but result in higher rates of relapse-free survival than the conventional dose of 100 to 400 milligrams.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.